New-Onset Atrial Fibrillation in the Critically Ill
Overview
Emergency Medicine
Authors
Affiliations
Objective: To determine the association of new-onset atrial fibrillation with outcomes, including ICU length of stay and survival.
Design: Retrospective cohort of ICU admissions. We found atrial fibrillation using automated detection (≥ 90 s in 30 min) and classed as new-onset if there was no prior diagnosis of atrial fibrillation. We identified determinants of new-onset atrial fibrillation and, using propensity matching, characterized its impact on outcomes.
Setting: Tertiary care academic center.
Patients: A total of 8,356 consecutive adult admissions to either the medical or surgical/trauma/burn ICU with available continuous electrocardiogram data.
Interventions: None.
Measurements And Main Results: From 74 patient-years of every 15-minute observations, we detected atrial fibrillation in 1,610 admissions (19%), with median burden less than 2%. Most atrial fibrillation was paroxysmal; less than 2% of admissions were always in atrial fibrillation. New-onset atrial fibrillation was subclinical or went undocumented in 626, or 8% of all ICU admissions. Advanced age, acute respiratory failure, and sepsis were the strongest predictors of new-onset atrial fibrillation. In propensity-adjusted regression analyses, clinical new-onset atrial fibrillation was associated with increased hospital mortality (odds ratio, 1.63; 95% CI, 1.01-2.63) and longer length of stay (2.25 d; CI, 0.58-3.92). New-onset atrial fibrillation was not associated with survival after hospital discharge (hazard ratio, 0.99; 95% CI, 0.76-1.28 and hazard ratio, 1.11; 95% CI, 0.67-1.83, respectively, for subclinical and clinical new-onset atrial fibrillation).
Conclusions: Automated analysis of continuous electrocardiogram heart rate dynamics detects new-onset atrial fibrillation in many ICU patients. Though often transient and frequently unrecognized, new-onset atrial fibrillation is associated with poor hospital outcomes.
The Ear, the Heart, and the Lung: The Mighty Mite.
Susai Manickam D, Ravichandran U Cureus. 2025; 17(1):e77658.
PMID: 39968422 PMC: 11834754. DOI: 10.7759/cureus.77658.
Ho W, Umais M, Bai M, Dang N, Kumari K, Izhar S Cardiol Res. 2025; 16(1):1-14.
PMID: 39897439 PMC: 11779681. DOI: 10.14740/cr1723.
Zakynthinos G, Tsolaki V, Xanthopoulos A, Karavidas N, Vazgiourakis V, Bardaka F J Clin Med. 2024; 13(22).
PMID: 39597893 PMC: 11595098. DOI: 10.3390/jcm13226750.
Chen Y, Yang Z, Liu Y, Gue Y, Zhong Z, Chen T Cardiovasc Diabetol. 2024; 23(1):426.
PMID: 39593120 PMC: 11590403. DOI: 10.1186/s12933-024-02521-7.
Edoxaban pharmacokinetics during in vitro continuous renal replacement therapy.
Wenzler E, Dalton K, Andrews L, Benken S BMC Nephrol. 2024; 25(1):341.
PMID: 39390394 PMC: 11468074. DOI: 10.1186/s12882-024-03777-7.